

GLP-1 TREATMENT OPTIONS AT A GLANCE

Nestlé Health Science is not a manufacturer of GLP-1 receptor agonist (RA) therapies. Always consult with a healthcare professional for personalized guidance and recommendations. It is important for patients taking GLP-1 therapies to consider their nutritional needs.

Generic Name	Brand Name(s)	Method of Administration & Frequency	Approved Uses (FDA/EMA)
Semaglutide	Ozempic®	Weekly - Under the skin (subcutaneous) injection	Type 2 diabetes (FDA & EMA) Reduce the risk of major adverse cardiovascular events in adults with T2D and established CVD (FDA & EMA)
	Wegovy®	Weekly - Under the skin (subcutaneous) injection	Obesity/weight management (FDA & EMA)
	Rybelsus®	Daily - Oral pill	Type 2 diabetes (FDA & EMA)
Dulaglutide	Trulicity®	Weekly - Under the skin (subcutaneous) injection	Type 2 diabetes (FDA & EMA); CV risk reduction in T2D with CVD (FDA)
Liraglutide	Victoza®	Daily - Under the skin (subcutaneous) injection	Type 2 diabetes (FDA & EMA); CV risk reduction in T2D with CVD (FDA)
	Saxenda®	Daily - Under the skin (subcutaneous) injection	Obesity/weight management (FDA & EMA)
Exenatide - immediate release	Byetta	Twice Daily - Under the skin (subcutaneous) injection	Type 2 diabetes (FDA & EMA)
Exenatide - extended release	Bydureon®	Weekly - Under the skin (subcutaneous) injection	Type 2 diabetes (FDA & EMA)
Lixisenatide	Adlyxin® (discontinued) (Lyxumia® in EU)	Daily - Under the skin (subcutaneous) injection	Type 2 diabetes (FDA & EMA)
Tirzepatide (dual GIP/GLP-1)	Mounjaro®	Weekly - Under the skin (subcutaneous) injection	Type 2 diabetes (FDA & EMA); Obesity/weight management (EMA)
	Zepbound®	Weekly - Under the skin (subcutaneous) injection	Obesity/weight management (FDA)

CV – Cardiovascular; **CVD** – Cardiovascular disease; **EMA** – European Medicines Agency; **FDA** – Food and Drug Administration; **T2D** – Type 2 Diabetes

Current FDA [<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>] and EMA [<https://www.ema.europa.eu/en/medicines>] labels